argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
01 Maio 2025 - 2:00AM
May 1, 2025Amsterdam,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that it will host a conference call and audio webcast on Thursday,
May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first
quarter 2025 financial results and provide a business update.
A webcast of the live call may be accessed on
the Investors section of the argenx website at
argenx.com/investors. A replay of the webcast will be available on
the argenx website for approximately one year following the
presentation.
Dial-in numbers:
Belgium
32 800 50 201France
33 800
943355Netherlands
31 20 795 1090United Kingdom 44 800 358 0970United
States
1 888 415 4250Japan
81 3
4578
9081Switzerland
41 43 210 11 32
Use the access code 3810049 to join the call.
Please dial in 15 minutes prior to the live call.
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx developed and is commercializing
the first approved neonatal Fc receptor (FcRn) blocker and is
evaluating its broad potential in multiple serious autoimmune
diseases while advancing several earlier stage experimental
medicines within its therapeutic franchises. For more information,
visit www.argenx.com and follow us
on LinkedIn, Instagram, Facebook,
and YouTube.
Contacts
Media:
Ben Petokbpetok@argenx.com
Investors:
Alexandra Royaroy@argenx.com
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Jun 2025 até Jul 2025
argenx (NASDAQ:ARGX)
Gráfico Histórico do Ativo
De Jul 2024 até Jul 2025
